Jacek Klepacki1, Jost Klawitter2, Jelena Klawitter2, Anis Karimpour-Fard3, Joshua Thurman4, Gordon Ingle5, Dharmesh Patel5, Uwe Christians2. 1. iC42 Clinical Research and Development, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. Electronic address: jacek.klepacki@ucdenver.edu. 2. iC42 Clinical Research and Development, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. 3. Center for Computational Biology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. 4. Division of Nephrology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States. 5. Novartis Pharmaceuticals, East Hanover, NJ, United States.
Abstract
BACKGROUND: The results of plasma amino acid patterns in samples from kidney transplant patients with good and impaired renal function using a targeted LC-MS/MS amino acid assay and a non-targeted metabolomics assay were compared. METHODS: EDTA plasma samples were prospectively collected at baseline, 1, 2, 4 and 6months post-transplant (n=116 patients, n=398 samples). Each sample was analyzed using both a commercial amino acid LC-MS/MS assay and a non-targeted metabolomics assay also based on MS/MS ion transitions. The results of both assays were independently statistically analyzed to identify amino acids associated with estimated glomerular filtration rates using correlation and partial least squares-discriminant analysis. RESULTS: Although there was overlap between the results of the targeted and non-targeted metabolomics assays (tryptophan, 1-methyl histidine), there were also substantial inconsistencies, with the non-targeted assay resulting in more "hits" than the targeted assay. Without further verification of the hits detected by the non-targeted discovery assay, this would have led to different interpretation of the results. There were also false negative results when the non-targeted assay was used (hydroxy proline). Several of said discrepancies could be explained by loss of sensitivity during analytical runs for selected amino acids (serine and threonine), retention time shifts, signals above the range of linear detector response and integration of peaks not separated from background and interferences (aspartate) when the non-targeted metabolomics assay was used. CONCLUSIONS: Whenever assessment of a specific pathway such as amino acids is the focus of interest, a targeted seems preferable to a non-targeted metabolomics assay.
BACKGROUND: The results of plasma amino acid patterns in samples from kidney transplant patients with good and impaired renal function using a targeted LC-MS/MS amino acid assay and a non-targeted metabolomics assay were compared. METHODS:EDTA plasma samples were prospectively collected at baseline, 1, 2, 4 and 6months post-transplant (n=116 patients, n=398 samples). Each sample was analyzed using both a commercial amino acid LC-MS/MS assay and a non-targeted metabolomics assay also based on MS/MS ion transitions. The results of both assays were independently statistically analyzed to identify amino acids associated with estimated glomerular filtration rates using correlation and partial least squares-discriminant analysis. RESULTS: Although there was overlap between the results of the targeted and non-targeted metabolomics assays (tryptophan, 1-methyl histidine), there were also substantial inconsistencies, with the non-targeted assay resulting in more "hits" than the targeted assay. Without further verification of the hits detected by the non-targeted discovery assay, this would have led to different interpretation of the results. There were also false negative results when the non-targeted assay was used (hydroxy proline). Several of said discrepancies could be explained by loss of sensitivity during analytical runs for selected amino acids (serine and threonine), retention time shifts, signals above the range of linear detector response and integration of peaks not separated from background and interferences (aspartate) when the non-targeted metabolomics assay was used. CONCLUSIONS: Whenever assessment of a specific pathway such as amino acids is the focus of interest, a targeted seems preferable to a non-targeted metabolomics assay.
Authors: Fernando Andrade; Juan Rodríguez-Soriano; José Angel Prieto; Javier Elorz; Mireia Aguirre; Gema Ariceta; Sergio Martin; Pablo Sanjurjo; Luis Aldámiz-Echevarría Journal: Pediatr Res Date: 2008-08 Impact factor: 3.756
Authors: Jessica M Hoffman; Corinna Ross; ViLinh Tran; Daniel E L Promislow; Suzette Tardif; Dean P Jones Journal: Am J Primatol Date: 2018-12-26 Impact factor: 2.371
Authors: Jesse A Davidson; Benjamin S Frank; Tracy T Urban; Mark Twite; James Jaggers; Ludmila Khailova; Jelena Klawitter Journal: Pediatr Nephrol Date: 2021-05-05 Impact factor: 3.651
Authors: Jesse D Hinckley; Laura Saba; Kristen Raymond; Karsten Bartels; Jost Klawitter; Uwe Christians; Christian Hopfer Journal: Cannabis Cannabinoid Res Date: 2020-06-19
Authors: Miguel Ruiz-Canela; Adela Hruby; Clary B Clish; Liming Liang; Miguel A Martínez-González; Frank B Hu Journal: J Am Heart Assoc Date: 2017-09-28 Impact factor: 5.501